SeraCare, NCI to Develop Cancer Diagnostics
SeraCare Life Sciences and the National Cancer Institute have partnered to develop reference materials and positive controls for cancer assays.
Specifically, the two organizations will generate methods to mix and quantify control DNA biosynthetics spiked into a genomic DNA background and cell-free circulating tumor DNA for next-generation DNA sequencing applications. SeraCare announced the cooperative research and development agreement Friday.
The plan is for the control materials to serve as quality control materials that can determine an assay’s ability to detect mutations, and help create more targeted medicines, SeraCare says. — Jason Scott